Showing papers by "Kapil D. Sethi published in 2016"

ADCY5mutations are another cause of benign hereditary choreaAuthor Response

Abstract: Editors' Note: In WriteClick this week, Morgan et al. and authors Mencacci et al. discuss the need to replace the term benign hereditary chorea in light of better knowledge of the syndrome since the term was coined. Dr. Chamberlain asks for clarification on several methodologic points in reference to “Standard chemoradiation for glioblastoma results in progressive brain volume loss.” The authors respond. —Megan Alcauskas, MD, and Robert C. Griggs, MD We read the report by Mencacci et al.1 with interest. While we agree it is important to consider ADCY5 mutations for children …

Ropinirole for the Treatment of Early Parkinson Disease

Abstract: A prospective, randomized, placebo-controlled, double-blind, parallel-group, 6-month study assessed the efficacy and safety of ropinirole, a nonergoline D2-dopamine agonist, in patients with early Parkinson's disease (n = 241; Hoehn & Yahr stages I to III) with limited or no prior dopaminergic therapy. Patients (mean age, 62.8 years), stratified by concomitant use of selegiline, were randomized to ropinirole (n= 116) or placebo (n = 125). The starting dose of ropinirole was 0.25 mg tid with titration to at least 1.5 mg tid (maximum dose, 8 mg tid). Primary efficacy endpoint was the percentage improvement in Unified Parkinson's Disease Rating Scale (UPDRS) motor score. Ropinirole-treated patients had a significantly greater percentage improvement in UPDRS motor score than patients who received placebo (+24% vs -3%; p < 0.001). Ropinirole was well tolerated and patient withdrawals were infrequent. Most adverse experiences were related to peripheral dopaminergic activity. Ropinirole monotherapy is an effective and well-tolerated therapeutic option for treatment of early Parkinson's disease.